Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rellafup-α plus chemotherapy with or without intraperitoneal chemotherapy for first-line HER2-negative gastric/GEJ adenocarcinoma with peritoneal metastasis
ChiCTR2600133373Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of retlirafusp alfa in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: 6-month progression-free survival rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600133373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133373.